Antigenics Oncophage On Hold After Phase III Failure, Conflicting Preliminary Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Antigenics is shifting its focus to its Phase I and preclinical development programs following the failure of its therapeutic vaccine Oncophage in a Phase III renal cell carcinoma (RCC) trial, the company said
You may also be interested in...
Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product